This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Nkarta Therapeutics Inc. raised $114mm through its Series B round. First-time investor Samsara BioCapital led and was joined by other new investors Amgen Ventures, Deerfield Management, Life Sciences Partners, Logos Capital, and RA Capital Management, along with returning backers NEA Ventures, Novo Holdings AS, and SR One. Nkarta is developing engineered natural killer cell therapies for cancer and will use the Series B funds to support trials with NKX101, an allogenic NK cell therapy targeting NKG2D for solid and blood cancers, and IND-enabling studies with a CAR-NK project targeting CD19 for B-cell malignancies. In connection with the round, Samsara and Life Sciences Partners joined Nkarta's board.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?